These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 33221920

  • 1. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
    Pilania RK, Jindal AK, Johnson N, Prithvi A, Vignesh P, Suri D, Rawat A, Gupta A, Singh S.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3413-3419. PubMed ID: 33221920
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 01; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 3. Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches.
    Han SB, Lee SY.
    World J Pediatr; 2020 Dec 01; 16(6):566-574. PubMed ID: 32418074
    [Abstract] [Full Text] [Related]

  • 4. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 01; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 5. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.
    Ebato T, Ogata S, Ogihara Y, Fujimoto M, Kitagawa A, Takanashi M, Ishii M.
    J Pediatr; 2017 Dec 01; 191():140-144. PubMed ID: 29173297
    [Abstract] [Full Text] [Related]

  • 6. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 Dec 01; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 7. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 01; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 8. Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease.
    Rivera-Rodriguez L, Pardo-Díaz E, Moreno-Espinosa S, Scheffler-Mendoza S, Ruiz-Ontiveros MA, Garrido-García LM, Iglesias-Amaya A, Yamazaki-Nakashimada MA.
    J Pediatr Hematol Oncol; 2021 Apr 01; 43(3):e448-e451. PubMed ID: 32079989
    [Abstract] [Full Text] [Related]

  • 9. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 01; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 10. Corticosteroids for the treatment of Kawasaki disease in children.
    Wardle AJ, Connolly GM, Seager MJ, Tulloh RM.
    Cochrane Database Syst Rev; 2017 Jan 27; 1(1):CD011188. PubMed ID: 28129459
    [Abstract] [Full Text] [Related]

  • 11. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children.
    Lee PY, Day-Lewis M, Henderson LA, Friedman KG, Lo J, Roberts JE, Lo MS, Platt CD, Chou J, Hoyt KJ, Baker AL, Banzon TM, Chang MH, Cohen E, de Ferranti SD, Dionne A, Habiballah S, Halyabar O, Hausmann JS, Hazen MM, Janssen E, Meidan E, Nelson RW, Nguyen AA, Sundel RP, Dedeoglu F, Nigrovic PA, Newburger JW, Son MBF.
    J Clin Invest; 2020 Nov 02; 130(11):5942-5950. PubMed ID: 32701511
    [Abstract] [Full Text] [Related]

  • 12. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW.
    J Am Heart Assoc; 2016 Sep 15; 5(9):. PubMed ID: 27633390
    [Abstract] [Full Text] [Related]

  • 13. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
    Kitoh T, Ohara T, Muto T, Okumura A, Baba R, Koizumi Y, Yamagishi Y, Mikamo H, Daigo K, Hamakubo T.
    Front Immunol; 2021 Sep 15; 12():624802. PubMed ID: 33912155
    [Abstract] [Full Text] [Related]

  • 14. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H, Chi H, You H, Wang M, Zhang G, Yang H, Li Q.
    BMC Pediatr; 2019 May 17; 19(1):158. PubMed ID: 31101091
    [Abstract] [Full Text] [Related]

  • 15. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
    Hashino K, Ishii M, Iemura M, Akagi T, Kato H.
    Pediatr Int; 2001 Jun 17; 43(3):211-7. PubMed ID: 11380911
    [Abstract] [Full Text] [Related]

  • 16. Kawasaki Disease: Beyond IVIG and Aspirin.
    Moussa T, Wagner-Weiner L.
    Pediatr Ann; 2019 Oct 01; 48(10):e400-e405. PubMed ID: 31609999
    [Abstract] [Full Text] [Related]

  • 17. Refractory Kawasaki disease: modified methylprednisolone regimen decreases coronary artery dilatation.
    Zhang M, Zheng Y, Li X, Yang S, Shi L, Li A, Liu Y.
    Pediatr Res; 2022 May 01; 91(6):1542-1550. PubMed ID: 34021270
    [Abstract] [Full Text] [Related]

  • 18. [Methylprednisolone pulse therapy in Kawasaki disease].
    Miura M, Matsuoka M, Kohno K, Ohki H, Yoshiba S.
    Nihon Rinsho; 2008 Feb 01; 66(2):338-42. PubMed ID: 18265457
    [Abstract] [Full Text] [Related]

  • 19. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 01; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 20. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.